<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7049568/results/search/drug/results.xml">
  <result pre="two decades after the approval of oseltamivir.3 Similar to oseltamivir," exact="Xofluza" post="needs to be administered within 48 h of influenza"/>
  <result pre="viral polymerase inhibitor (baloxavir marboxil [Xofluza] approved in 2018).2,3,36 However," exact="amantadine" post="and its derivatives are no longer used because 100%"/>
  <result pre="was purified using TRIzol (Invitrogen, Carlsbad, CA, USA), followed by" exact="ethanol" post="precipitation. m7G-capped NS1shRNAs were prepared by replacing the guanosine"/>
  <result pre="old (Jackson Laboratories, Bar Harbor, ME, USA), were anesthetized with" exact="isoflurane" post="and administered (5 mice/group) 25 μg of 5′-PPP-NS1shRNA, capped-NS1shRNA,"/>
  <result pre="global seasonal influenza-associated respiratory mortality: a modelling studyLancet39120181285130029248255 36WendelH.A.SnyderM.T.PellS.Trial of" exact="amantadine" post="in epidemic influenzaClin. Pharmacol. Ther.7196638435325584 37collab: Centers for Disease"/>
 </snippets>
</snippetsTree>
